Art. -Nr.: HY-50907

ABT-737

71 Cited Publications

Kundenbewertung

Based on 71 publication(s) in Google Scholar

ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-x_L and Bcl-w inhibitor with EC₅₀s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.64%
CAS. Nr.: 852808-04-9
Formel: C₄₂H₄₅ClN₆O₅S₂
Molecular Weight:813.43

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

ABT-737 Chemical Structure

CAS. Nr.: 852808-04-9

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (71)
Lösungsmittel & Löslichkeit
- In Vitro
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

Bcl-2

30.3 nM (EC₅₀)

Bcl-xL

78.7 nM (EC₅₀)

Bcl-W

197.8 nM (EC₅₀)

Bcl-B

1820 nM (EC₅₀)

Bfl-1

>10 μM (EC₅₀)

Mcl-1

>10 μM (EC₅₀)

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	IC₅₀	0.74 μM Compound: 1, ABT-737	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
DOHH-2	EC₅₀	0.0083 μM Compound: 2, ABT-737	Inhibition of cell growth in human DoHH2 cells overexpressing Bcl2 in presence of 3% FBS Inhibition of cell growth in human DoHH2 cells overexpressing Bcl2 in presence of 3% FBS	[PMID: 17256834]
DOHH-2	EC₅₀	0.13 μM Compound: 2, ABT-737	Inhibition of cell growth in human DoHH2 cells overexpressing Bcl2 in presence of 10% HS Inhibition of cell growth in human DoHH2 cells overexpressing Bcl2 in presence of 10% HS	[PMID: 17256834]
DU-145	IC₅₀	27.6 μM Compound: 7, ABT-737	Cytotoxicity against human DU145 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human DU145 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
FL5.12	EC₅₀	0.008 μM Compound: 2, ABT-737	Reversal of cytokine withdrawal protection in IL3 dependent Bcl2 overexpressing mouse FL5.12 cells in presence of bovine gelatin Reversal of cytokine withdrawal protection in IL3 dependent Bcl2 overexpressing mouse FL5.12 cells in presence of bovine gelatin	[PMID: 17256834]
FL5.12	EC₅₀	0.03 μM Compound: 2, ABT-737	Reversal of cytokine withdrawal protection in IL3 dependent Bcl-xL overexpressing mouse FL5.12 cells in presence of bovine gelatin Reversal of cytokine withdrawal protection in IL3 dependent Bcl-xL overexpressing mouse FL5.12 cells in presence of bovine gelatin	[PMID: 17256834]
FL5.12	EC₅₀	0.05 μM Compound: 2, ABT-737	Reversal of cytokine withdrawal protection in IL3 dependent Bcl2 overexpressing mouse FL5.12 cells in presence of 3% FBS Reversal of cytokine withdrawal protection in IL3 dependent Bcl2 overexpressing mouse FL5.12 cells in presence of 3% FBS	[PMID: 17256834]
FL5.12	EC₅₀	0.22 μM Compound: 2, ABT-737	Reversal of cytokine withdrawal protection in IL3 dependent Bcl-xL overexpressing mouse FL5.12 cells in presence of 3% FBS Reversal of cytokine withdrawal protection in IL3 dependent Bcl-xL overexpressing mouse FL5.12 cells in presence of 3% FBS	[PMID: 17256834]
FL5.12	EC₅₀	30 nM Compound: 1, ABT-737	Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl-XL assessed as cell viability after 24 hrs by MTS assay in absence of serum Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl-XL assessed as cell viability after 24 hrs by MTS assay in absence of serum	[PMID: 18841882]
FL5.12	EC₅₀	7.7 nM Compound: 1, ABT-737	Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl2 assessed as cell viability after 24 hrs by MTS assay in absence of serum Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl2 assessed as cell viability after 24 hrs by MTS assay in absence of serum	[PMID: 18841882]
HCT-116	IC₅₀	4.06 μM Compound: 7, ABT-737	Cytotoxicity against human HCT116 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HCT116 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HCT-116	IC₅₀	47.7 μM Compound: ABT-737	Cytotoxicity against human HCT116 cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay	[PMID: 22172701]
HL-60	IC₅₀	0.76 μM Compound: 1, ABT-737	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
HL-60	IC₅₀	0.97 μM Compound: ABT-737	Growth inhibition of human HL60 cells after 72 hrs by MTT assay Growth inhibition of human HL60 cells after 72 hrs by MTT assay	[PMID: 27712939]
Jurkat	IC₅₀	1.38 μM Compound: 7, ABT-737	Cytotoxicity against human Jurkat cells after 48 hrs by cell titer-blue assay Cytotoxicity against human Jurkat cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
K562	IC₅₀	34.7 μM Compound: 1, ABT-737	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
K562	IC₅₀	16.4 μM Compound: ABT-737	Induction of apoptosis in Mcl1 dependent human K562 cells after 48 hrs by Annexin V staining based flow cytometry Induction of apoptosis in Mcl1 dependent human K562 cells after 48 hrs by Annexin V staining based flow cytometry	[PMID: 23314054]
Leukemia cell	IC₅₀	>1 μM Compound: 1, ABT-737	Binding affinity to human/mouse chimeric Mcl-1 by luminescence proximity assay Binding affinity to human/mouse chimeric Mcl-1 by luminescence proximity assay	[PMID: 23767404]
Leukemia cell	IC₅₀	>10 μM Compound: 1, ABT-737	Binding affinity to human/mouse chimeric Mcl-1 by surface plasmon resonance assay Binding affinity to human/mouse chimeric Mcl-1 by surface plasmon resonance assay	[PMID: 23767404]
MCF7	IC₅₀	21.26 μM Compound: 7, ABT-737	Cytotoxicity against human MCF7 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human MCF7 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
MCF7	IC₅₀	25.33 μM Compound: ABT-737	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 27712939]
MCF7	EC₅₀	4.39 μM Compound: ABT-737	Antiproliferative activity against cisplatin-resistant human MCF7-CR cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against cisplatin-resistant human MCF7-CR cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 35421577]
MDA-MB-435	IC₅₀	>122.94 μM Compound: ABT-737	Cytotoxicity against human MDA-MB-435 cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay	[PMID: 22172701]
MEF	EC₅₀	>10000 nM Compound: 1, ABT-737	Cytotoxicity against mouse MEF cells expressing mcl-1 fl/fl after 24 hrs by Cell titer glo assay in presence of 10% serum Cytotoxicity against mouse MEF cells expressing mcl-1 fl/fl after 24 hrs by Cell titer glo assay in presence of 10% serum	[PMID: 21366295]
MEF	EC₅₀	2.03 nM Compound: 1, ABT-737	Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 1% serum Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 1% serum	[PMID: 21366295]
MEF	EC₅₀	51 nM Compound: 1, ABT-737	Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% fetal bovine serum Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% fetal bovine serum	[PMID: 21366295]
MEF	EC₅₀	51 nM Compound: 1, ABT-737	Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% serum Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% serum	[PMID: 21366295]
MEF	EC₅₀	>10000 nM Compound: 1, ABT-737	Cytotoxicity against mouse MEF cells expressing mcl-1 fl/fl after 24 hrs by Cell titer glo assay in presence of 1% serum Cytotoxicity against mouse MEF cells expressing mcl-1 fl/fl after 24 hrs by Cell titer glo assay in presence of 1% serum	[PMID: 21366295]
MEF	EC₅₀	0.013 μM Compound: 1; ABT-737	Cytotoxicity against MCL deficient mouse embryonic fibroblast cells assessed as reduction in cell viability in presence of 1 % fetal calf serum measured after 24 hrs by propidium iodide staining based flow cytometric analysis Cytotoxicity against MCL deficient mouse embryonic fibroblast cells assessed as reduction in cell viability in presence of 1 % fetal calf serum measured after 24 hrs by propidium iodide staining based flow cytometric analysis	[PMID: 33904752]
MOLT-4	EC₅₀	622 nM Compound: 20	Antiproliferative activity against human MOLT4 cells in presence of 10% human serum Antiproliferative activity against human MOLT4 cells in presence of 10% human serum	[PMID: 28926247]
MOLT-4	IC₅₀	227 nM Compound: ABT-263	Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay	[PMID: 32145645]
NCI-H1417	IC₅₀	0.13 μM Compound: 1, ABT-737	Growth inhibition of human NCI-H1417 cells after 4 days by WST8 assay Growth inhibition of human NCI-H1417 cells after 4 days by WST8 assay	[PMID: 22448988]
NCI-H1417	IC₅₀	412 nM Compound: 1, ABT-737	Antiproliferative activity against human NCI-H1417 cells after 4 days by WST8 assay Antiproliferative activity against human NCI-H1417 cells after 4 days by WST8 assay	[PMID: 22747598]
NCI-H1417	IC₅₀	173.4 nM Compound: 1, ABT-737	Cytotoxicity against human NCI-H1417 cells assessed as growth inhibition after 4 days by WST assay Cytotoxicity against human NCI-H1417 cells assessed as growth inhibition after 4 days by WST assay	[PMID: 23448298]
NCI-H146	EC₅₀	0.087 μM Compound: 1, ABT-737	Cytotoxicity against human NCI-H146 cells assessed as cell viability after 48 hrs in presence of 10% human serum Cytotoxicity against human NCI-H146 cells assessed as cell viability after 48 hrs in presence of 10% human serum	[PMID: 18841882]
NCI-H146	IC₅₀	0.097 μM Compound: 1, ABT-737	Growth inhibition of human NCI-H146 cells after 4 days by WST8 assay Growth inhibition of human NCI-H146 cells after 4 days by WST8 assay	[PMID: 22448988]
NCI-H146	IC₅₀	37 nM Compound: 1, ABT-737	Antiproliferative activity against human NCI-H146 cells after 4 days by WST8 assay Antiproliferative activity against human NCI-H146 cells after 4 days by WST8 assay	[PMID: 22747598]
NCI-H146	IC₅₀	43.8 nM Compound: ABT-263	Antiproliferative activity against human NCI-H146 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay Antiproliferative activity against human NCI-H146 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay	[PMID: 32145645]
NCI-H187	IC₅₀	137.7 nM Compound: 1, ABT-737	Cytotoxicity against human NCI-H187 cells assessed as growth inhibition after 4 days by WST assay Cytotoxicity against human NCI-H187 cells assessed as growth inhibition after 4 days by WST assay	[PMID: 23448298]
NCI-H1963	IC₅₀	59 nM Compound: 1, ABT-737	Antiproliferative activity against human NCI-H1963 cells after 4 days by WST8 assay Antiproliferative activity against human NCI-H1963 cells after 4 days by WST8 assay	[PMID: 22747598]
NCI-H1963	IC₅₀	54 nM Compound: 1, ABT-737	Cytotoxicity against human NCI-H1963 cells assessed as growth inhibition after 4 days by WST assay Cytotoxicity against human NCI-H1963 cells assessed as growth inhibition after 4 days by WST assay	[PMID: 23448298]
NCI-H23	IC₅₀	71.16 μM Compound: ABT-737	Growth inhibition of human NCI-H23 cells after 72 hrs by MTT assay Growth inhibition of human NCI-H23 cells after 72 hrs by MTT assay	[PMID: 27712939]
NCI-H460	IC₅₀	8.03 μM Compound: 7, ABT-737	Cytotoxicity against human H460 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human H460 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
Platelet	IC₅₀	242 nM Compound: ABT-263	Toxicity in human platelet assessed as reduction in cell viability measured after 48 hrs by MTS assay Toxicity in human platelet assessed as reduction in cell viability measured after 48 hrs by MTS assay	[PMID: 32145645]
Raji	IC₅₀	93.49 μM Compound: ABT-737	Cytotoxicity against human Raji cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay Cytotoxicity against human Raji cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay	[PMID: 22172701]
RS4-11	IC₅₀	0.27 μM Compound: ABT-737	Induction of apoptosis in Bcl2 dependent human RS4:11 cells after 48 hrs by Annexin V staining based flow cytometry Induction of apoptosis in Bcl2 dependent human RS4:11 cells after 48 hrs by Annexin V staining based flow cytometry	[PMID: 23314054]
RS4-11	EC₅₀	24 nM Compound: 20	Antiproliferative activity against human RS4:11 cells in presence of 10% human serum Antiproliferative activity against human RS4:11 cells in presence of 10% human serum	[PMID: 28926247]
RS4-11	IC₅₀	0.33 μM Compound: ABT-737	Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29453135]
RS4-11	IC₅₀	49 nM Compound: ABT-263	Antiproliferative activity against human RS4-11 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay Antiproliferative activity against human RS4-11 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay	[PMID: 32145645]
SK-OV-3	IC₅₀	46.59 μM Compound: ABT-737	Growth inhibition of human SKOV3 cells after 72 hrs by MTT assay Growth inhibition of human SKOV3 cells after 72 hrs by MTT assay	[PMID: 27712939]
SU.86.86	IC₅₀	4.24 μM Compound: 7, ABT-737	Cytotoxicity against human SU-8686 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human SU-8686 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
SUD4	EC₅₀	0.22 μM Compound: 2, ABT-737	Inhibition of cell growth in human SUDHL4 cells overexpressing Bcl2 in presence of 3% FBS Inhibition of cell growth in human SUDHL4 cells overexpressing Bcl2 in presence of 3% FBS	[PMID: 17256834]
SUD4	EC₅₀	0.85 μM Compound: 2, ABT-737	Inhibition of cell growth in human SUDHL4 cells overexpressing Bcl2 in presence of 10% HS Inhibition of cell growth in human SUDHL4 cells overexpressing Bcl2 in presence of 10% HS	[PMID: 17256834]
U-266	IC₅₀	27.35 μM Compound: ABT-737	Growth inhibition of human U266 cells after 72 hrs by MTT assay Growth inhibition of human U266 cells after 72 hrs by MTT assay	[PMID: 27712939]

In Vitro

ABT-737 binds BCL-2, BCL-X_L, and BCL-W with high affinity (K_i<1 nM) but binds weakly (K_i>460 nM) to other antiapoptotic BCL-2 family members, including MCL-1 and BFL-1. ABT-737 binds the BH3-binding groove of BCL-X_L and BCL-2^[1].
ABT-737 (100 nM; 1-72 hours) induces apoptosis and synergizes with chemotherapy in HL-60 cells^[1].
ABT-737 (5, 7.5, 10 μM; 72 hours) causes approximately 80% HCT116 cell death. The BAX knockout variant is completely resistant to ABT-737^[1].
ABT-737 has no effect on cell cycle distribution. ABT-737 disrupts BCL-2/BAX heterodimerization and induces BAX conformational change in HL-60 leukemic cells^[1].
ABT-737 induces a BAX/BAK-dependent impairment of maximal O₂ consumption rate in sensitive cells. Stable BCL-2 overexpression in MCF10A cells induces an ABT-737-sensitive primed for death state. ABT-737 induces dose-dependent impairment of maximal O₂ consumption rate in B-cell lymphoma cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ABT-737 (20, 30 mg/kg/day; i.p.; for 21 days) suppresses the leukemia burden by 48% and 53% at the 20 and 30 mg/kg dose levels, respectively, in four- to six-week-old CB.17 Scid mice with human leukemia KG-1 cells^[1].
ABT-737 significantly extends survival of mice in this aggressive leukemia model^[1].
ABT-737 (50 mg/kg; i.p.; once a day; for 5 days) is highly selective for lymphoid cells and inhibited allogeneic T- and B-cell responses after skin transplantation in mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 852808-04-9
Appearance Solid
Molecular Weight 813.43
Formel C₄₂H₄₅ClN₆O₅S₂
Color Yellow to orange
SMILES

CN(CC[C@@H](NC1=CC=C(C=C1[N+]([O-])=O)S(NC(C2=CC=C(C=C2)N3CCN(CC3)CC4=CC=CC=C4C5=CC=C(C=C5)Cl)=O)(=O)=O)CSC6=CC=CC=C6)C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (71)

All IFWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cancer Cell

Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer. [Abstract]

2023 Jul 10;41(7):1242-1260.e6. PMID: 37267953

ABT-737 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2023 Jul 10;41(7):1242-1260.e6. [Abstract]

Immunofluorescence staining of FoxP3 and CD4 in tumorigenic KY-FDR lungs, at 8 weeks after tumor induction, after vehicle (A), DT (A′), or ABT-737 (25 mg/kg, once per week) (A″) treatment. Tumor lesions are defined by dashed lines.
Cell

Sublethal cytochrome c release generates drug-tolerant persister cells. [Abstract]

2022 Sep 1;185(18):3356-3374.e22. PMID: 36055199

ABT-737 purchased from MedChemExpress. Usage Cited in: Cell. 2022 Sep 1;185(18):3356-3374.e22. [Abstract]

Immunoblot of endogenous ATF4, APAF1 and CASPASE9 in PC9 cells after transient expression of Cas9 and either sgNT, sgAPAF1 or sgCASPASE9. Cells were treated with ABT-737 1μM and S6 2μM for 6h.
Nat Immunol

Exclusion of Notch from the contact site during efferocytosis restricts anticancer immunity. [Abstract]

2026 Mar 3. PMID: 41776100
Cell Stem Cell

Senolytic-sensitive p16Ink4a+ fibroblasts in the tumor stroma rewire lung cancer metabolism and plasticity. [Abstract]

2025 Dec 4;32(12):1869-1885.e8. PMID: 41187746
Cell Mol Immunol

VRK2 is involved in the innate antiviral response by promoting mitostress-induced mtDNA release. [Abstract]

2021 May;18(5):1186-1196. PMID: 33785841
Nat Aging

Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome. [Abstract]

2026 Feb 3. PMID: 41634464
Nat Cell Biol

DNA fragmentation factor B suppresses interferon to enable cancer persister cell regrowth. [Abstract]

2025 Dec;27(12):2143-2151. PMID: 41249572
Mol Cell

The human antibacterial factor APOL3 couples lysosomal damage to mitochondrial DNA efflux and type I IFN induction. [Abstract]

2026 Feb 24:S1097-2765(26)00071-7. PMID: 41742416
Nat Commun

The formation of the 'footprint of death' as a mechanism for generating large substrate-bound extracellular vesicles that mark the site of cell death. [Abstract]

2025 Oct 15;16(1):9160. PMID: 41093830
Nat Commun

Attenuated growth factor signaling during cell death initiation sensitizes membranes towards peroxidation. [Abstract]

2025 Feb 25;16(1):1774. PMID: 40000627

ABT-737 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 25;16(1):1774. [Abstract]

NIH-3T3 fibroblasts were pre-treated (45 h) with vehicle, VAL (10 µM) or ABT-737 (10 µM) and then with RSL3 (5 µM, 3 h). Immunofluorescence images (representative of ≥ 25 single cells, n = 3, scale bar: 20 µm) stained for 4-HNE, cleaved (cl.) caspase 3 and nuclei (DAPI) and stained cells (h, lower panels).
Nat Commun

ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. [Abstract]

2023 Sep 19;14(1):5709. PMID: 37726279
Cell Death Differ

Ca2+-mediated mitochondrial inner membrane permeabilization induces cell death independently of Bax and Bak. [Abstract]

2022 Jul;29(7):1318-1334. PMID: 35726022

ABT-737 purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2022 Jul;29(7):1318-1334. [Abstract]

Immunoblot analysis showing release of soluble mitochondrial proteins into the cytosol after treatment with 25 μM m-3M3FBS or a combination of Bcl-2/Bcl-xL (5 μM ABT-737) and Mcl-1 (5 μM S63845) inhibitors for 20 and 40 min followed by digitonin permeabilization in HeLa cells. To synchronize the onset of MOMP, cells were primed with a sublethal dose of UV irradiation (5 mJ/cm²) 16 h prior to ABT-737 plus S63845 addition. Data are representative of n = 3 independent experiments.

ABT-737 purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2022 Jul;29(7):1318-1334. [Abstract]

Confocal microscopy analysis showing release of the IMS proteins omi-mCherry (red) and the Matrix proteins mito-GCaMP3 (green) in HeLa cells after 10 min treatment with 5 μM ABT-737 or 25 μM m-3M3FBS. To synchronize the onset of MOMP, cells were primed with a sublethal dose of UV irradiation (5 mJ/cm²) 16 h prior to ABT-737 addition. Data are representative of n = 3 independent experiments. Scale bar = 40 μm.

ABT-737 purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2022 Jul;29(7):1318-1334. [Abstract]

Cell death quantification of HeLa WT and Bax,Bak DKO cells after 6 h of treatment with 25 μM m-3M3FBS or 5 μM ABT-737 + 5 μM S63845 in combination (A/S) with 40 μM qVD and/or 40 μM Calpain Inhibitor III (Calp.i). Error bars represent the SD from the mean of triplicate samples. Error bars represent the SD from the mean of n = 3 independent experiments.
Adv Sci (Weinh)

The Oxysterol Receptor EBI2 Links Innate and Adaptive Immunity to Limit IFN Response and Systemic Lupus Erythematosus. [Abstract]

2023 Sep;10(27):e2207108. PMID: 37469011
Cell Rep Med

A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. [Abstract]

2024 May 29:101592. PMID: 38843841
Cancer Lett

Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. [Abstract]

2019 Oct 1:461:102-111. PMID: 31319139

ABT-737 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2019 Oct 1:461:102-111. [Abstract]

Expression of active (cleaved) PARP and active (cleaved) Caspase-3 after 48h of treatment with AGS, 1 μM ABT-737 or 1 μM ABT-737 added to AGS as determined by Western blot. Floating cells are included in lysate.
Cell Death Dis

A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factors. [Abstract]

2020 Nov 15;11(11):982. PMID: 33191401
Proc Natl Acad Sci U S A

Endocytosis triggers V-ATPase-SYK-mediated priming of cGAS activation and innate immune response. [Abstract]

2022 Oct 25;119(43):e2207280119. PMID: 36252040
Phytomedicine

Piperine targets SOAT1 to inhibit the progression of esophageal squamous cell carcinoma via ferroptosis. [Abstract]

2025 Sep 25:148:157332. PMID: 41061292
Haematologica

Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. [Abstract]

2017 Apr;102(4):755-764. PMID: 28104700
Aging Cell

Morphofunctional Heterogeneity and Plasticity of Glioblastoma Cells Induced to Senescence by Temozolomide. [Abstract]

2026 Apr;25(4):e70477. PMID: 41963773
Cell Death Discov

Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer. [Abstract]

2025 Sep 25;11(1):423. PMID: 40998801
Cell Death Discov

LINC complex protein nesprin-2 has pro-apoptotic activity via Bcl-2 family proteins. [Abstract]

2024 Jan 15;10(1):29. PMID: 38225256
Neurotherapeutics

Transcriptionally distinct malignant neuroblastoma populations show selective response to adavosertib treatment. [Abstract]

2025 Apr;22(3):e00575. PMID: 40118716
Cell Rep

The N-degron pathway mediates the autophagic degradation of cytosolic mitochondrial DNA during sterile innate immune responses. [Abstract]

2024 Dec 21;44(1):115094. PMID: 39709605
Cell Rep

Cardiolipin oxidized by ROS from complex II acts as a target of gasdermin D to drive mitochondrial pore and heart dysfunction in endotoxemia. [Abstract]

2024 May 15;43(5):114237. PMID: 38753484
Cell Rep

ZYG11B potentiates the antiviral innate immune response by enhancing cGAS-DNA binding and condensation. [Abstract]

2023 Mar 17;42(3):112278. PMID: 36933219
Cell Rep

RhoA/Cdc42 signaling drives cytoplasmic maturation but not endomitosis in megakaryocytes. [Abstract]

2021 May 11;35(6):109102. PMID: 33979620
Clin Transl Med

IRF4 contributes to chemoresistance in IGH::BCL2-positive diffuse large B-cell lymphomas by mediating BCL2-induced SOX9 expression. [Abstract]

2025 May;15(5):e70336. PMID: 40356256
Pharmaceutics

Navitoclax Enhances the Therapeutic Effects of PLK1 Targeting on Lung Cancer Cells in 2D and 3D Culture Systems. [Abstract]

2022 Jun 6;14(6):1209. PMID: 35745782
Pharmaceutics

pH-Responsive i-motif Conjugated Hyaluronic Acid/Polyethylenimine Complexes for Drug Delivery Systems. [Abstract]

2019 May 27;11(5):247. PMID: 31137791
Chem Biol Interact

Different concentrations of betaxolol switch cell fate between necroptosis, apoptosis, and senescence in human corneal stromal cells. [Abstract]

2024 Mar 1:391:110898. PMID: 38325520
Biomolecules

Targeting Cellular Senescence to Enhance Human Endometrial Stromal Cell Decidualization and Inhibit Their Migration. [Abstract]

2025 Jun 16;15(6):873. PMID: 40563513
Eur J Pharm Sci

Penehyclidine hydrochloride regulates mitochondrial dynamics and apoptosis through p38MAPK and JNK signal pathways and provides cardioprotection in rats with myocardial ischemia-reperfusion injury. [Abstract]

2018 Aug 30:121:243-250. PMID: 29860115
Toxicology

Proteasome inhibition induces apoptosis through simultaneous inactivation of MCL-1/BCL-XL by NOXA independent of CHOP and JNK pathways. [Abstract]

2024 Aug 6:153906. PMID: 39117261
J Cell Mol Med

LAPTM5 Confers the Resistance to Venetoclax via Promoting the Autophagosome-Lysosome Fusion in Multiple Myeloma. [Abstract]

2025 Jan;29(1):e70331. PMID: 39753521
Exp Neurol

Neuronal aerobic glycolysis exacerbates synapse loss in aging mice. [Abstract]

2024 Jan:371:114590. PMID: 37907123
J Cell Mol Med

Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells. [Abstract]

2023 Jan;27(1):76-88. PMID: 36523175
J Ovarian Res

Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. [Abstract]

2016 Apr 14;9(1):25. PMID: 27080533
ACS Med Chem Lett

High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma. [Abstract]

2015 Jun 22;6(8):948-52. PMID: 26288699
Cell Signal

PERK-eIF2alpha-mediated translational inhibition of MCL-1 contributes to potential 2-deoxy-D-glucose and BAD mimetic combinatorial cancer therapy. [Abstract]

2025 Dec 19:139:112333. PMID: 41423011
J Cell Sci

Charcot-Marie-Tooth type 2A variants of mitofusin 2 sensitize cells to apoptotic cell death. [Abstract]

2025 Sep 15;138(18):jcs263691. PMID: 40995860
Viruses

DNAJ Homolog Subfamily C Member 11 Stabilizes SARS-CoV-2 NSP3 to Promote Double-Membrane Vesicle Formation. [Abstract]

2025 Jul 22;17(8):1025. PMID: 40872740
Phytochemistry

Monoterpene-chalcone conjugates and diarylheptanoids isolated from the seeds of Alpinia katsumadai Hayata with cytotoxic activity. [Abstract]

2024 Jun 28:114197. PMID: 38945281
Mol Carcinog

Hsa_circ_0000231 Accelerates Cell Autophagy and Promotes Cell Proliferation and Invasion of Colorectal Cancer via miR-140-3p/Bcl-2 Axis. [Abstract]

2025 Mar 26. PMID: 40135563
Immunopharmacol Immunotoxicol

Astragaloside IV restores Th17/Treg balance via inhibiting CXCR4 to improve chronic obstructive pulmonary disease. [Abstract]

2023 Dec;45(6):682-691. PMID: 37417915
Am J Cancer Res

Panoramic analysis of cell death patterns reveals prognostic and immune profiles of head and neck squamous cell carcinoma. [Abstract]

2024 May 15;14(5):2584-2607. PMID: 38859838
Clin Transl Sci

Computational drug discovery pipelines identify NAMPT as a therapeutic target in neuroendocrine prostate cancer. [Abstract]

2024 Sep;17(9):e70030. PMID: 39295559
J Phys Chem A

Real-Time Growth Kinetics Analysis of Macromolecular Assemblies in Cells with Single Molecule Resolution. [Abstract]

2023 Apr 20;127(15):3490-3496. PMID: 37023388
Int J Biochem Cell Biol

Bad is essential for Bcl-xL-enhanced Bax shuttling between mitochondria and cytosol. [Abstract]

2023 Feb:155:106359. PMID: 36586532
Theriogenology

Eicosatrienoic acid enhances the quality of in vitro matured porcine oocytes by reducing PRKN-mediated ubiquitination of CISD2. [Abstract]

2024 Sep 24:230:285-298. PMID: 39357167
Biol Chem

Inhibition of miR-143-3p alleviates myocardial ischemia reperfusion injury via limiting mitochondria-mediated apoptosis. [Abstract]

2023 Feb 14;404(6):619-631. PMID: 36780323
Biochem Biophys Res Commun

BID- and BAX-mediated mitochondrial pathway dominates A-1331852-induced apoptosis in senescent A549 cells. [Abstract]

2022 Oct 30:627:160-167. PMID: 36041325
Biochem Biophys Res Commun

BAK plays a key role in A-1331852-induced apoptosis in senescent chondrocytes. [Abstract]

2022 Jun 18;609:93-99. PMID: 35421634
In Vitro Cell Dev Biol Anim

TLR9/FCRL3 regulates B cell viability, apoptosis, and antibody and IL-10 production through ERK1/2, p38, and STAT3 signaling pathways. [Abstract]

2022 Sep;58(8):702-711. PMID: 36121575
bioRxiv

2026 Jun 25.
bioRxiv

2026 Mar 28.
Dental Research

2026 Mar 24.
bioRxiv

2026 Feb 25.
bioRxiv

DFFB suppresses interferon to enable cancer persister cell regrowth. [Abstract]

2025 Aug 21:2025.08.15.670603. PMID: 40894800
Norges teknisk-naturvitenskapelige universitet

2025.
bioRxiv

The antibacterial factor APOL3 couples lysosomal damage to mitochondrial DNA efflux and type I IFN induction. [Abstract]

2025 May 19:2025.05.16.654477. PMID: 40475483
Norges teknisk-naturvitenskapelige universitet

2024.
bioRxiv

Senescent fibroblasts in the tumor stroma rewire lung cancer metabolism and plasticity. [Abstract]

2024 Jul 30:2024.07.29.605645. PMID: 39131266
University of Minnesota

2024.
Research Square Preprint

2023 Oct 6.
Research Square Preprint

2023 Oct 9.
bioRxiv

2023 Sep 7.
Research Square Preprint

2023 Jul 7.
University of Groningen

2020 Jan.
Moscow State University

2019 Jul.
bioRxiv

September 11, 2018.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 66.67 mg/mL (81.96 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2294 mL

6.1468 mL

12.2936 mL

5 mM

0.2459 mL

1.2294 mL

2.4587 mL

10 mM

0.1229 mL

0.6147 mL

1.2294 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Protokoll

Kinase Assay^[1]

To determine the binding affinity of GST-BCL-2 family proteins to the FITC-conjugated BH3 domain of BIM (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR), FPAs are performed as follows. Briefly, 100 nM of GST-BCL-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-BIM BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. IC₅₀s are determined using GraphPad Prism software.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[3]

Cells are treated with ABT-737, ABT-263, or vehicle (DMSO) for 4 h in XF24 assay medium (6×10⁴ MCF10A cells, see medium composition below) or RPMI 1640 medium (1×10⁶ B-cell lymphoma cells) and apoptosis is analyzed by Annexin-V-binding/PI exclusion or by sub-diploid nuclei determination. FACS analysis is performed on Becton Dickinson FACScan or FACScalibur instruments. Data analysis is performed with CellQuest software.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Konopleva M, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006 Nov;10(5):375-88. [Content Brief]

[2]. Ahamed Saleem, et al. Effect of dual inhibition of apoptosis and autophagy in prostate cancer. Prostate. 2012 Sep 1;72(12):1374-81. [Content Brief]

[3]. Clerc P, et al. Polster BM.Rapid Detection of an ABT-737-Sensitive Primed for Death State in Cells Using Microplate-Based Respirometry.PLoS One. 2012;7(8):e42487. Epub 2012 Aug 3. [Content Brief]

[4]. Cippà PE, et al. The BH3-mimetic ABT-737 inhibits allogeneic immune responses. Transpl Int. 2011 Jul;24(7):722-32. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2294 mL	6.1468 mL	12.2936 mL	30.7341 mL
	5 mM	0.2459 mL	1.2294 mL	2.4587 mL	6.1468 mL
	10 mM	0.1229 mL	0.6147 mL	1.2294 mL	3.0734 mL
	15 mM	0.0820 mL	0.4098 mL	0.8196 mL	2.0489 mL
	20 mM	0.0615 mL	0.3073 mL	0.6147 mL	1.5367 mL
	25 mM	0.0492 mL	0.2459 mL	0.4917 mL	1.2294 mL
	30 mM	0.0410 mL	0.2049 mL	0.4098 mL	1.0245 mL
	40 mM	0.0307 mL	0.1537 mL	0.3073 mL	0.7684 mL
	50 mM	0.0246 mL	0.1229 mL	0.2459 mL	0.6147 mL
	60 mM	0.0205 mL	0.1024 mL	0.2049 mL	0.5122 mL
	80 mM	0.0154 mL	0.0768 mL	0.1537 mL	0.3842 mL

Keywords

ABT-737

71 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

ABT-737

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Peptidomimetic Library

Anti-Aging Compound Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Targeted Diversity Library

Protein-protein Interaction Inhibitor Library

Anti-Prostate Cancer Compound Library

Mitochondrial Protection Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) ABT-737

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (71)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

ABT-737

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Peptidomimetic Library

Anti-Aging Compound Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Targeted Diversity Library

Protein-protein Interaction Inhibitor Library

Anti-Prostate Cancer Compound Library

Mitochondrial Protection Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) ABT-737

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (71)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

ABT-737 Related Classifications

Art. -Nr.: HY-50907